Plasma concentration of atorvastatin metabolites correlates with low‐density lipoprotein cholesterol reduction in patients with coronary heart disease
Open Access
- 26 April 2023
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 11 (3) , e01089
Abstract
In this exploratory study from a randomized double‐blinded crossover trial including 70 patients with coronary heart disease and self‐perceived muscular side effects of statins, we aimed to determine the relationship between low‐density lipoprotein cholesterol (LDL‐C) reduction and atorvastatin metabolite plasma concentrations. All patients underwent a 7 weeks treatment period with atorvastatin 40 mg/day and a 7 weeks placebo period in random order. Nonlinear regression with a three‐parameter equation explored the relationship between percentage LDL‐C reduction (statin vs. placebo) and the pharmacokinetic variables. Mean LDL‐C reduction was 49% (range 12% to 71%). The sum of 4‐OH‐atorvastatin acid and lactone correlated moderately with the LDL‐C response (Spearman ρ 0.27, 95% confidence interval [CI]: 0.03 to 0.48). Accordingly, nonlinear regression showed R2 of 0.14 (95% CI: 0.03 to 0.37, R2 adjusted equaled 0.11). Even a perfect underlying correlation of 1.0 showed R2 = 0.32 by simulation, using historical intra‐individual LDL‐C variation (8.5%). The 90% inhibitory concentration was 2.1 nmol/L, and the 4‐OH‐metabolite sum exceeded this threshold in 34% of the patients. In conclusion, trough plasma concentrations of 4‐OH‐atorvastatin metabolites correlated moderately to the LDL‐C reduction. A plateau LDL‐C response was observed above a pharmacokinetic threshold, below which the response was highly variable. The usefulness of monitoring concentrations of atorvastatin metabolites to optimize the individual dosage have limitations, but its supportive potential may be pursued in relevant patient subsets to achieve adequate efficacy at the lowest possible dose. The results add knowledge to the overall understanding of the variable LDL‐C response mediated by atorvastatin.Keywords
This publication has 28 references indexed in Scilit:
- Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statinsNature Communications, 2014
- Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular EventsJACC, 2014
- Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical CareCirculation: Cardiovascular Genetics, 2013
- Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol ReductionCirculation: Cardiovascular Genetics, 2012
- Statins PersonalizedMedical Clinics of North America, 2012
- Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)The American Journal of Cardiology, 2010
- Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) CohortCirculation: Cardiovascular Genetics, 2009
- Clinical Pharmacokinetics of AtorvastatinClinical Pharmacokinetics, 2003
- Pharmacodynamics and Pharmacokinetic‐Pharmacodynamic Relationships of Atorvastatin, an HMG‐CoA Reductase InhibitorThe Journal of Clinical Pharmacology, 2000
- Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.Circulation, 1992